*Nauclea latifolia* (African peach, *opepe* in Yoruba) and *Cryptolepis sanguinolenta* (Ghanaian-distributed but used across Igbo and Yoruba ethnomedicine) are the two principal West African antimalarials used by traditional healers for febrile illness in children. Both contain indole alkaloids with documented schizonticidal activity.
Work from the University of Ibadan's Department of Pharmacognosy (P. A. Akah, A. Sofowora, C. O. Adewunmi, M. M. Iwu) and the OAU Department of Pharmaceutical Chemistry isolated the cryptolepine alkaloid from *Cryptolepis* and several oxindole alkaloids from *Nauclea*, published across *Journal of Ethnopharmacology*, *Planta Medica* and *Phytotherapy Research* from the 1980s onward.
Mechanism studies confirmed haem polymerase inhibition similar to that of chloroquine. Phase I clinical trials of *Cryptolepis* preparations were conducted in Ghana (Centre for Scientific Research into Plant Medicine, Mampong) in the 1990s; Nigerian Phase I work was institutional and small.
What did not happen: an industrial-scale extraction plant, a finished standardised drug, or a Phase III trial. In the same window, Chinese researchers took *Artemisia annua* — used in Chinese traditional medicine — through complete pharmaceutical development, won the 2015 Nobel Prize in Medicine, and became the global supplier of every artemisinin combination therapy Nigeria now imports.
The two histories are exact mirrors of each other, told at the same time, with the same kind of plant, and the same kind of starting evidence. One country built the institutional bridge; the other did not.